Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company dedicated to developing AAV vector-based gene therapies for rare central nervous system (CNS) diseases. The company’s proprietary platform harnesses tissue-specific promoters and a streamlined development process to address a range of inherited neurological disorders. Taysha’s lead programs are focused on monogenic diseases with high unmet medical need, and its approach aims to deliver durable, one-time treatments that can modify disease progression.
The company’s pipeline includes TSHA-102 for Rett syndrome, TSHA-104 for GM1 gangliosidosis, TSHA-105 for giant axonal neuropathy and TSHA-118 for frontotemporal dementia (FTD) associated with progranulin deficiency. Each candidate employs an adeno-associated virus serotype optimized for CNS delivery and a promoter designed to drive expression in relevant neuronal or glial cell populations. Taysha has reported encouraging preclinical and early clinical data across several programs, demonstrating target engagement and favorable safety profiles in initial cohorts.
Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies was established by a team of gene therapy veterans with backgrounds at leading academic institutions and biotechnology firms. The company has entered strategic collaborations with academic centers and contract development and manufacturing organizations to accelerate vector production and clinical supply. Taysha’s R&D operations leverage both in-house capabilities and external partnerships to support IND filings and ongoing trials in North America and Europe.
Under the leadership of Chief Executive Officer Mona Sinha, a seasoned executive with extensive experience in translational research and drug development, Taysha continues to expand its footprint in the rare disease community. The management team includes experts in regulatory affairs, clinical operations and vector biology. Taysha is committed to engaging patient advocacy groups and shaping disease awareness, aiming to bring transformative gene therapies to underserved patient populations worldwide.
AI Generated. May Contain Errors.